Douglas C. Marchion
- Molecular Biology top 5%
- Oncology top 5%
- Cancer Research top 10%
- Immunology
- Pulmonary and Respiratory Medicine
- Co-authors
- Pamela N. MünsterElona BiçakuDaniel M. SullivanAdil DaudMorgen SchmittJoel G. TurnerAndrea BassoNeal Rosen
- Topics
- Histone Deacetylase Inhibitors Research (19 papers)Protein Degradation and Inhibitors (14 papers)Ovarian cancer diagnosis and treatment (12 papers)
- Partner nations
- United StatesAustraliaFrance
In The Last Decade
Douglas C. Marchion
63 papers receiving 2.2k citations
Peers
Comparison fields: 5 of 105
- Molecular Biology 1.8k
- Oncology 609
- Cancer Research 253
- Immunology 156
- Pulmonary and Respiratory Medicine 155
Countries citing papers authored by Douglas C. Marchion
This map shows the geographic impact of Douglas C. Marchion's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas C. Marchion with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas C. Marchion more than expected).
Fields of papers citing papers by Douglas C. Marchion
This network shows the impact of papers produced by Douglas C. Marchion. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas C. Marchion. The network helps show where Douglas C. Marchion may publish in the future.
Co-authorship network of co-authors of Douglas C. Marchion
This figure shows the co-authorship network connecting the top 25 collaborators of Douglas C. Marchion. A scholar is included among the top collaborators of Douglas C. Marchion based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas C. Marchion. Douglas C. Marchion is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 8 | |
| 3 | 3 | |
| 4 | 15 | |
| 5 | 111 | |
| 6 | 5 | |
| 7 | 9 | |
| 8 | 7 | |
| 9 | 42 | |
| 10 | 25 | |
| 11 | 91 | |
| 12 | 8 | |
| 13 | 19 | |
| 14 | 78 | |
| 15 | 135 | |
| 16 | The histone deacetylase inhibitor-induced potentiation of tamoxifen involves autophagy. | 1 |
| 17 | Valproic acid sensitizes human melanoma cells to karenitecin in vitro and in vivo | 0 |
| 18 | 154 | |
| 19 | Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. | 130 |
| 20 | 1 |
About Douglas C. Marchion
Douglas C. Marchion is a scholar working on Reproductive Medicine, Cancer Research and Oncology, having authored 66 papers that have together received 2.3k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (19 papers), Protein Degradation and Inhibitors (14 papers) and Ovarian cancer diagnosis and treatment (12 papers). The work is most often cited by research in Molecular Biology (1.8k citations), Oncology (609 citations) and Cancer Research (253 citations). Douglas C. Marchion has collaborated with scholars based in United States, Australia and France. Frequent co-authors include Pamela N. Münster, Elona Biçaku, Daniel M. Sullivan, Adil Daud, Morgen Schmitt, Joel G. Turner, Andrea Basso, Neal Rosen, Scott Thomas and Johnathan M. Lancaster. Their work appears in journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.